HIV and immunotherapy drug demand is strong. GlaxoSmithKline plc Sponsored ADR (GSK.US) raises full-year performance guidance.

Benefiting from the growth in demand for its HIV and immunology drugs, GlaxoSmithKline plc Sponsored ADR (GSK.US) has raised its full-year profit and sales expectations. The financial report shows that the company's Q3 revenue reached 8.55 billion pounds, a year-on-year increase of 4.9%, exceeding expectations by 300 million pounds; earnings per share excluding certain items increased by 11% to 0.55 pounds, compared to analysts' previous expectation of 0.47 pounds. GlaxoSmithKline plc Sponsored ADR expects earnings per share excluding certain items to increase by as much as 12% this year, higher than the previously forecasted maximum increase of 8%. Revenue could increase by as much as 7%, also higher than previous estimates. Chief Business Officer Luke Miles will take over as CEO in January, facing the same challenge as current CEO Walmsley in convincing investors that the company's in-development drug pipeline can achieve sales of over 40 billion pounds (53 billion US dollars) by 2031. GlaxoSmithKline plc Sponsored ADR's portfolio of specialty drug products, including immunology drugs for diseases such as HIV, cancer, and lupus, is expected to drive growth. Benefiting from demand in Europe, drugs such as Dovato for HIV treatment and Benlysta for lupus treatment have helped boost sales, and the performance of the vaccine business exceeded expectations. Other developers like Sanofi and CSL have issued warnings about declining vaccination rates in the US. GlaxoSmithKline plc Sponsored ADR struck two early-stage deals this week to enhance its product pipeline before the expiration of patents on its best-selling HIV drugs. Unlike local competitor AstraZeneca PLC Sponsored ADR, GlaxoSmithKline plc Sponsored ADR has not reached an agreement with the Trump administration aimed at mitigating the impact of industry tariffs and new regulations through price reductions. GlaxoSmithKline plc Sponsored ADR stated that its full-year guidance has taken into account current tariffs and the potential imposition of a 15% tariff in Europe.